Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
12.12
+0.18 (1.51%)
At close: Jun 10, 2025, 4:00 PM
12.72
+0.60 (4.95%)
After-hours: Jun 10, 2025, 5:42 PM EDT
Centessa Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 10 professional analysts, the 12-month price target for Centessa Pharmaceuticals stock ranges from a low of $11 to a high of $38. The average analyst price target of $27 forecasts a 122.77% increase in the stock price over the next year.
Price Target: $27.00 (+122.77%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Centessa Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 6 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 9 | 9 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Initiates $35 | Strong Buy | Initiates | $35 | +188.78% | May 28, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +147.52% | May 8, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $38 | Buy | Initiates | $38 | +213.53% | Mar 31, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +131.02% | Mar 26, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $27 | Buy | Initiates | $27 | +122.77% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
9.18M
Revenue Next Year
n/a
from 9.18M
EPS This Year
-1.49
from -2.06
EPS Next Year
-1.58
from -1.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.8M | n/a | n/a | ||
| Avg | 9.2M | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.25 | -1.24 | -1.14 | ||
| Avg | -1.49 | -1.58 | -1.69 | ||
| Low | -1.72 | -1.97 | -2.28 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.